Purpose: Cs-131 has an implied advantage of shortening the duration of side-effects due to
its shorter half-life (9.7 days) versus I-125 (59.4 days). Over 90 patients have had
permanent prostate implant brachytherapy with Cs-131 seeds at Geisinger Medical Center
since March 2006. Patients are routinely followed with serial IPSS to assess the extent
of their urinary symptoms.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
PO173
Identification
Copyright
© 2008 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
